Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
What is your approach to management of severe osteoporosis in patients with advanced kidney disease?
Do you consider anabolic agents and if so, what is your approach to monitoring?
Related Questions
Is elevated bone specific alkaline phosphatase an absolute contraindication to teriparatide?
What range of musculoskeletal complaints have you seen with romosozumab use?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
Is it safe to combine Prolia with other immunosuppressants?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Do you recommend osteoporosis medication in postmenopausal females on anastrozole with very low Vitamin D (4.5)?
Would you consider PTH-analog therapy in a woman with osteoporotic vertebral fractures who has asymptomatic non-obstructive renal stones and normal 24-hour urine calcium level?
Would you consider anabolic osteoporosis therapy in a young adult male with multiple non-traumatic vertebral compression fractures and low bone density for age (Z-score -2.6)?
How do you use P1NP in your clinical practice to guide management of osteoporosis?